TBPH Theravance Biopharma Inc

Price (delayed)

$9.47

Market cap

$471.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.61

Enterprise value

$449.9M

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives ...

Highlights
TBPH's revenue is up by 6% since the previous quarter and by 6% year-on-year
The gross profit has grown by 6% from the previous quarter and by 6% YoY
The company's quick ratio has surged by 70% YoY but it fell by 20% QoQ
The net income has plunged by 107% YoY and by 107% from the previous quarter
Theravance Biopharma's EPS has shrunk by 105% YoY and by 105% QoQ

Key stats

What are the main financial stats of TBPH
Market
Shares outstanding
49.8M
Market cap
$471.59M
Enterprise value
$449.9M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.03
Price to sales (P/S)
9.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.25
Earnings
Revenue
$54.51M
EBIT
-$56.24M
EBITDA
-$49.54M
Free cash flow
-$150.76M
Per share
EPS
-$0.61
Free cash flow per share
-$2.88
Book value per share
$4.66
Revenue per share
$1.04
TBVPS
$7.9
Balance sheet
Total assets
$413.59M
Total liabilities
$167.46M
Debt
$50.83M
Equity
$246.13M
Working capital
$136.32M
Liquidity
Debt to equity
0.21
Current ratio
6.37
Quick ratio
5.99
Net debt/EBITDA
0.44
Margins
EBITDA margin
-90.9%
Gross margin
100%
Net margin
-104.7%
Operating margin
-123.3%
Efficiency
Return on assets
-11.4%
Return on equity
-17%
Return on invested capital
-15.6%
Return on capital employed
-14.5%
Return on sales
-103.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TBPH stock price

How has the Theravance Biopharma stock price performed over time
Intraday
0.74%
1 week
9.16%
1 month
-5.58%
1 year
-12.31%
YTD
-15.75%
QTD
-15.75%

Financial performance

How have Theravance Biopharma's revenue and profit performed over time
Revenue
$54.51M
Gross profit
$54.51M
Operating income
-$67.23M
Net income
-$57.05M
Gross margin
100%
Net margin
-104.7%
The net income has plunged by 107% YoY and by 107% from the previous quarter
Theravance Biopharma's net margin has shrunk by 106% YoY and by 106% QoQ
Theravance Biopharma's operating margin has surged by 51% YoY and by 13% QoQ
The operating income is up by 49% YoY and by 7% QoQ

Growth

What is Theravance Biopharma's growth rate over time

Valuation

What is Theravance Biopharma stock price valuation
P/E
N/A
P/B
2.03
P/S
9.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.25
Theravance Biopharma's EPS has shrunk by 105% YoY and by 105% QoQ
TBPH's equity is down by 49% year-on-year and by 12% since the previous quarter
The price to book (P/B) is 7% higher than the last 4 quarters average of 1.9
The P/S is 39% lower than the 5-year quarterly average of 14.9 and 27% lower than the last 4 quarters average of 12.5
TBPH's revenue is up by 6% since the previous quarter and by 6% year-on-year

Efficiency

How efficient is Theravance Biopharma business performance
The ROIC has plunged by 111% YoY and by 105% from the previous quarter
The company's return on assets has shrunk by 108% QoQ and by 106% YoY
The ROE has plunged by 108% from the previous quarter
Theravance Biopharma's return on sales has shrunk by 105% YoY and by 105% QoQ

Dividends

What is TBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TBPH.

Financial health

How did Theravance Biopharma financials performed over time
Theravance Biopharma's total assets is 147% more than its total liabilities
TBPH's current ratio has surged by 77% year-on-year but it is down by 19% since the previous quarter
The company's quick ratio has surged by 70% YoY but it fell by 20% QoQ
Theravance Biopharma's debt is 79% lower than its equity
The debt to equity has soared by 91% YoY and by 17% QoQ
TBPH's equity is down by 49% year-on-year and by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.